MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Wednesday, March 4, 2026. The Company’s management will discuss the results during a ...

Core Insights - Sight Sciences, Inc. reported preliminary financial highlights for Q4 and full year 2025, indicating a mixed performance with Q4 revenue growth but an overall decline for the year [1][5]. Financial Performance - Q4 2025 total revenue is expected to be between $20.3 million and $20.4 million, reflecting a 7% increase at the estimated midpoint compared to the same period last year [2]. - Full year 2025 total revenue is projected to be between $77.3 million and $77.4 million, representing a 3% decrease at the estimated midpoint compared to the previous year [3]. - Cash and cash equivalents as of December 31, 2025, were approximately $92 million, slightly down from $92.4 million as of September 30, 2025 [4]. Business Developments - The company achieved significant milestones in Dry Eye reimbursement and continued momentum in Surgical Glaucoma, with Dry Eye revenues expected to increase by approximately 130% compared to the prior year [5][7]. - Surgical Glaucoma revenues are anticipated to remain flat at the estimated midpoint compared to the previous year, with expected revenues between $75.6 million and $75.7 million [7]. - The company reported cash used in Q4 totaled approximately $0.4 million, with a total of approximately $28 million used during the year, indicating operational discipline [7]. Future Outlook - The company expressed confidence in its growth outlook and operational discipline, aiming for cash flow breakeven without requiring additional equity capital [5]. - Complete financial results for Q4 and full year 2025 are expected to be announced in March 2026 [5].

Core Insights - Sight Sciences, Inc. is an eyecare technology company focused on developing innovative interventional technologies to transform care and improve patients' lives [1][3] - The company will present at the Stifel 2025 Healthcare Conference on November 11, 2025, and at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 [2] Company Overview - Sight Sciences develops and commercializes minimally invasive or non-invasive solutions targeting prevalent eye diseases, aiming to enhance patient care and replace outdated treatment methods [3] - The company's key products include the OMNI Surgical System and OMNI Edge Surgical System, which are implant-free technologies for glaucoma surgery, and the TearCare System for treating evaporative dry eye disease [3] Product Details - The OMNI Surgical System is CE Marked for reducing intraocular pressure in adult patients with primary open-angle glaucoma [3] - The SION Surgical System is a bladeless device for excising trabecular meshwork in ophthalmic procedures [3] - The TearCare System is 510(k) cleared for localized heat therapy to clear gland obstructions in patients with meibomian gland disease [3]

Core Insights - The 24-month results from Stage 3 of the SAHARA trial demonstrate significant and sustained improvements in signs and symptoms of dry eye disease for participants treated with the TearCare System [1][3][5] - A majority of participants (66%) required no additional treatment after initial TearCare treatments, indicating the durability of the treatment effect [2][7] Study Results - All mean signs and symptoms remained statistically significantly better than the study baseline at all measured time points up to 24 months [2][5] - Tear breakup time (TBUT) improved from a baseline of 4.41 seconds to a range of 6.29 to 7.13 seconds at Month 24, with p<.0001 indicating strong statistical significance [5] - Meibomian Gland Secretion Score (MGSS) showed sustained improvement from Month 6 (7.26) to Month 24 (means ranging from 17.68 to 18.95), also with p<.0001 [5] - Subjective symptoms assessed by Ocular Surface Disease Index (OSDI), symptom assessment in dry eye (SANDE), and eye dryness score (EDS) remained significantly better than baseline values at all follow-up time points [5][6] Treatment Efficacy - The study confirmed that just two TearCare treatments within five months can lead to meaningful, lasting improvements for up to two years [3][9] - The median time for first retreatment was 7 months, with a 6-month retreatment-free survival probability of 92% [7]

Core Viewpoint - Sight Sciences, Inc. has launched the OMNI Edge Surgical System, enhancing its OMNI product family with advanced features for minimally invasive glaucoma surgery (MIGS) [1][2][5] Product Features - OMNI Edge incorporates TruSync™ technology, which synchronizes viscoelastic delivery with the surgeon's control, allowing for consistent deployment along Schlemm's canal [2][13] - The system features an expanded viscoelastic capacity of 21 µL, nearly double the previous 11 µL capacity of the OMNI Surgical System, while maintaining safety and usability [2][13] - OMNI Edge is designed to treat all three areas of resistance in the aqueous outflow system, making it versatile for various stages of primary open-angle glaucoma (POAG) [2][7] Clinical Insights - Early clinical use of OMNI Edge has been positively received, with enhancements in ergonomics and predictability noted by practitioners [3] - The OMNI procedure has demonstrated safety, effectiveness, and durability in over 300,000 procedures, establishing its leadership in canal-based MIGS [4] Market Position - The introduction of OMNI Edge allows surgeons to choose between OMNI and OMNI Edge technologies, catering to diverse surgical preferences and patient needs [5] - OMNI Edge is currently available only in the United States, indicating a focused market strategy [5] Company Commitment - Sight Sciences emphasizes its dedication to innovation in glaucoma care through ongoing collaboration with the ophthalmic community [4]